RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer.
RhoC is a member of the Ras-homologous family of genes which have been implicated in tumorigenesis and tumor progression. However, the exact role of RhoC is controversial and is yet to be clarified. We have examined the effect of RhoC on prostate tumor cells and found that RhoC had no effect on cell proliferation in vitro or on tumor growth in mice. However, RhoC significantly enhanced the metastatic ability of the tumor cells in these animals, suggesting that RhoC affects only the metastasis but not the growth of prostate tumor cells. The results of our immunohistochemical analyses on tumor specimens from 63 patients with prostate cancer indicate that RhoC expression had no significant correlation with Gleason grade. However, the expression of RhoC showed significant positive correlation with both lymph node and distant metastasis, and it was inversely correlated with patient survival. We also found that RhoC significantly augmented the invasion and motility of prostate tumor cells by activating matrix metalloproteinases 2 and 9 (MMP2 and MMP9) in vitro. The results of our antibody array analysis for signal molecules revealed that RhoC significantly activated kinases including mitogen-activated protein kinase (MAPK), focal adhesion kinase (FAK), Akt, and Pyk2. Inhibition of Pyk2 kinase blocked the RhoC-dependent activation of FAK, MAPK, and Akt, followed by the suppression of MMP2 and MMP9. Inhibitors of both MAPK and Akt also significantly blocked the activities of these MMPs. Therefore, our results indicate that RhoC promotes tumor metastasis in prostate cancer by sequential activation of Pyk2, FAK, MAPK, and Akt followed by the up-regulation of MMP2 and MMP9, which results in the stimulation of invasiveness of tumor cells.
Iiizumi
Megumi
M
Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA.
Bandyopadhyay
Sucharita
S
Pai
Sudha K
SK
Watabe
Misako
M
Hirota
Shigeru
S
Hosobe
Sadahiro
S
Tsukada
Taisei
T
Miura
Kunio
K
Saito
Ken
K
Furuta
Eiji
E
Liu
Wen
W
Xing
Fei
F
Okuda
Hiroshi
H
Kobayashi
Aya
A
Watabe
Kounosuke
K
D000818:Animals; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D004789:Enzyme Activation; D051417:Focal Adhesion Kinase 1 / Q000378:metabolism; D051418:Focal Adhesion Kinase 2 / Q000378:metabolism*; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis / Q000235:genetics; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis / Q000235:genetics; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D015398:Signal Transduction; D015854:Up-Regulation; D020741:rho GTP-Binding Proteins / Q000096:biosynthesis / Q000378:metabolism*; D000075024:rhoC GTP-Binding Protein
D051417:Focal Adhesion Kinase 1; D051418:Focal Adhesion Kinase 2; C496050:PTK2 protein, human; D020928:Mitogen-Activated Protein Kinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; C066690:RHOC protein, human; D020741:rho GTP-Binding Proteins; D000075024:rhoC GTP-Binding Protein
Clin Cancer Res. 2003 Nov 1;9(14):5282-6
14614010
Neoplasia. 2005 May;7(5):435-45
15967096
Head Neck. 1998 Dec;20(8):745-52
9790298
Oncogene. 2000 Mar 2;19(10):1318-28
10713673
Nat Rev Cancer. 2002 Feb;2(2):133-42
12635176
Mol Cell Biol. 2005 Aug;25(16):6889-98
16055703
Clin Cancer Res. 2000 Jun;6(6):2417-23
10873094
Nat Rev Cancer. 2001 Nov;1(2):162-8
11905808
Mol Ther. 2005 Feb;11(2):267-74
15668138
Cancer Res. 2007 Nov 15;67(22):10976-83
18006843
Prostate. 1986;9(3):261-81
3774632
Eur J Cancer. 2006 Jul;42(10):1455-65
16750623
Ann Surg Oncol. 1996 Jan;3(1):100-5
8770310
Clin Exp Metastasis. 2002;19(4):301-11
12090470
Oncogene. 1997 Jul 17;15(3):265-74
9233761
Cancer Metastasis Rev. 2006 Mar;25(1):9-34
16680569
Br J Cancer. 2004 Jun 14;90(12):2349-55
15150600
Clin Cancer Res. 2004 Feb 1;10(3):1192-200
14871999
J Invest Dermatol. 2006 Apr;126(4):862-8
16470169
Nat Cell Biol. 2000 May;2(5):249-56
10806474
Int J Cancer. 1996 Oct 9;68(2):164-71
8900422
Prog Biophys Mol Biol. 1999;71(3-4):435-78
10354709
Cancer Res. 2005 Jun 1;65(11):4698-706
15930288
Cancer Res. 2005 Nov 1;65(21):9762-70
16266997
J Cell Physiol. 2006 Jun;207(3):816-28
16508947
Cancer Res. 1999 Apr 15;59(8):2004-10
10213513
Cancer Res. 2004 Nov 1;64(21):7655-60
15520163
Mol Cell Biol. 2004 Apr;24(8):3526-35
15060171
Oncogene. 2006 Apr 13;25(16):2285-96
16314838
Cell. 2004 Jan 23;116(2):167-79
14744429
Clin Cancer Res. 2004 Apr 15;10(8):2742-50
15102679
Oncogene. 2004 Jan 8;23(1):157-67
14712221
Oncogene. 2001 May 10;20(21):2626-35
11420674
Cancer Res. 2007 Nov 1;67(21):10436-44
17974987
Exp Cell Res. 2004 Nov 15;301(1):43-9
15501444
Cancer Res. 2006 Mar 15;66(6):3153-61
16540666
Clin Cancer Res. 2003 Jan;9(1):215-22
12538472
Clin Cancer Res. 2004 Oct 1;10(19):6572-8
15475446
Eur J Biochem. 1999 Aug;263(3):605-11
10469123
Anticancer Res. 2004 Mar-Apr;24(2B):921-7
15161045
Nat Rev Cancer. 2005 Jul;5(7):505-15
16069815
Cancer Res. 2003 Apr 15;63(8):1731-6
12702552
Head Neck. 1998 Oct;20(7):634-9
9744465
J Biol Chem. 1998 Feb 27;273(9):5146-54
9478968
Endocrinology. 2004 Jul;145(7):3324-30
15070849
Cancer. 1999 Oct 15;86(8):1551-6
10526262
Breast Cancer Res Treat. 2005 Sep;93(2):101-10
16187229
Genes Dev. 2005 Sep 1;19(17):1974-9
16107613
J Biol Chem. 1999 Mar 26;274(13):8917-24
10085136
Clin Exp Metastasis. 2000;18(5):423-8
11467775